메뉴 건너뛰기




Volumn 92, Issue 2, 2014, Pages 111-120

Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells

Author keywords

Autophagy; Imatinib; Mammalian target of rapamycin signaling pathway; Ph+ acute lymphoblastic leukemia; Rapamycin

Indexed keywords

BCR ABL PROTEIN; CHLOROQUINE; IMATINIB; RAPAMYCIN;

EID: 84892670599     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12202     Document Type: Article
Times cited : (18)

References (41)
  • 1
    • 0021346853 scopus 로고
    • Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
    • Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
    • (1984) Cell , vol.36 , pp. 93-99
    • Groffen, J.1    Stephenson, J.R.2    Heisterkamp, N.3    de Klein, A.4    Bartram, C.R.5    Grosveld, G.6
  • 2
    • 0021811764 scopus 로고
    • Structural organization of the bcr gene and its role in the Ph' translocation
    • Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-61.
    • (1985) Nature , vol.315 , pp. 758-761
    • Heisterkamp, N.1    Stam, K.2    Groffen, J.3    de Klein, A.4    Grosveld, G.5
  • 3
    • 0025348013 scopus 로고
    • Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
    • Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 1990;247:1079-82.
    • (1990) Science , vol.247 , pp. 1079-1082
    • Lugo, T.G.1    Pendergast, A.M.2    Muller, A.J.3    Witte, O.N.4
  • 4
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford R, Capdeville JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
    • (2001) N Engl J Med , vol.344 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3    Resta, D.J.4    Reese, S.F.5    Ford, R.6    Capdeville, J.M.7    Capdeville, R.8    Talpaz, M.9
  • 5
    • 0037093092 scopus 로고    scopus 로고
    • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    • Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
    • (2002) Blood , vol.99 , pp. 3530-3539
    • Sawyers, C.L.1    Hochhaus, A.2    Feldman, E.3
  • 6
    • 67349233062 scopus 로고    scopus 로고
    • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    • Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
    • (2009) Leukemia , vol.23 , pp. 1054-1061
    • Hochhaus, A.1    O'Brien, S.G.2    Guilhot, F.3
  • 8
    • 64049089054 scopus 로고    scopus 로고
    • Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation
    • Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009;113:2902-5.
    • (2009) Blood , vol.113 , pp. 2902-2905
    • Bachanova, V.1    Verneris, M.R.2    DeFor, T.3    Brunstein, C.G.4    Weisdorf, D.J.5
  • 9
    • 76349087390 scopus 로고    scopus 로고
    • Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    • Wendy Stock.
    • Wendy Stock. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:188-98.
    • (2010) Leuk Lymphoma , vol.51 , pp. 188-198
  • 10
    • 42449165060 scopus 로고    scopus 로고
    • Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
    • Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707.
    • (2008) Leukemia , vol.22 , pp. 686-707
    • Steelman, L.S.1    Abrams, S.L.2    Whelan, J.3
  • 11
    • 32044465506 scopus 로고    scopus 로고
    • TOR signaling in growth and metabolism
    • Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
    • (2006) Cell , vol.124 , pp. 471-484
    • Wullschleger, S.1    Loewith, R.2    Hall, M.N.3
  • 12
    • 0025117392 scopus 로고
    • Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
    • Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
    • (1990) Science , vol.247 , pp. 824-830
    • Daley, G.Q.1    Van Etten, R.A.2    Baltimore, D.3
  • 13
    • 16844366670 scopus 로고    scopus 로고
    • ABLOncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors
    • Kharas MG, Fruman DA. ABLOncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-53.
    • (2005) Cancer Res , vol.65 , pp. 2047-2053
    • Kharas, M.G.1    Fruman, D.A.2
  • 14
    • 14644425319 scopus 로고    scopus 로고
    • Mechanisms of BCR-ABL the pathogenesis of chronic myelogenous leukaemia
    • Ren R. Mechanisms of BCR-ABL the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172-84.
    • (2005) Nat Rev Cancer , vol.5 , pp. 172-184
    • Ren, R.1
  • 15
    • 66149164593 scopus 로고    scopus 로고
    • Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
    • Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009;145:569-80.
    • (2009) Br J Haematol , vol.145 , pp. 569-580
    • Teachey, D.T.1    Grupp, S.A.2    Brown, V.I.3
  • 16
    • 1542327671 scopus 로고    scopus 로고
    • Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
    • Mohi MG, Boulton C, Gu TL. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci 2004;101:3130-5.
    • (2004) Proc Natl Acad Sci , vol.101 , pp. 3130-3135
    • Mohi, M.G.1    Boulton, C.2    Gu, T.L.3
  • 17
    • 77950069222 scopus 로고    scopus 로고
    • mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
    • Mancini M, Corradi V, Pettaa S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 2010;34:641-8.
    • (2010) Leuk Res , vol.34 , pp. 641-648
    • Mancini, M.1    Corradi, V.2    Pettaa, S.3    Martinelli, G.4    Barbieri, E.5    Santucci, M.A.6
  • 18
    • 51349108718 scopus 로고    scopus 로고
    • Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
    • Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-50.
    • (2008) J Clin Invest , vol.118 , pp. 3038-3050
    • Kharas, M.G.1    Janes, M.R.2    Scarfone, V.M.3    Lilly, M.B.4    Knight, Z.A.5    Shokat, K.M.6    Fruman, D.A.7
  • 19
    • 58549116685 scopus 로고    scopus 로고
    • Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor
    • Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res 2009;33:450-9.
    • (2009) Leuk Res , vol.33 , pp. 450-459
    • Hirase, C.1    Maeda, Y.2    Takai, S.3    Kanamaru, A.4
  • 21
    • 84866267909 scopus 로고    scopus 로고
    • Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line
    • Yang X, Lin J, Gong Y, Ma H, Shuai X, Zhou R, Guo Y, Shan Q, He G. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol 2012;30:123-30.
    • (2012) Hematol Oncol , vol.30 , pp. 123-130
    • Yang, X.1    Lin, J.2    Gong, Y.3    Ma, H.4    Shuai, X.5    Zhou, R.6    Guo, Y.7    Shan, Q.8    He, G.9
  • 22
    • 84868348363 scopus 로고    scopus 로고
    • Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway
    • Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012;13:1244-54.
    • (2012) Cancer Biol Ther , vol.13 , pp. 1244-1254
    • Guo, Y.1    Shan, Q.2    Gong, Y.3    Lin, J.4    Yang, X.5    Zhou, R.6
  • 23
    • 43049101649 scopus 로고    scopus 로고
    • Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs
    • Wang DG, Wang ZP, Tian BQ, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol 2008;15:435-41.
    • (2008) Int J Urol , vol.15 , pp. 435-441
    • Wang, D.G.1    Wang, Z.P.2    Tian, B.Q.3    Li, X.4    Li, S.5    Tian, Y.6
  • 24
    • 75749122303 scopus 로고    scopus 로고
    • Methods in mammalian autophagy research
    • Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26.
    • (2010) Cell , vol.140 , pp. 313-326
    • Mizushima, N.1    Yoshimori, T.2    Levine, B.3
  • 25
    • 74949100074 scopus 로고    scopus 로고
    • RAD001 (Everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia
    • Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA. RAD001 (Everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010;109:320-8.
    • (2010) J Cell Biochem , vol.109 , pp. 320-328
    • Mancini, M.1    Petta, S.2    Martinelli, G.3    Barbieri, E.4    Santucci, M.A.5
  • 26
    • 27144526660 scopus 로고    scopus 로고
    • Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
    • Burchert A, Wang Y, Cai D. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005;19:1774-82.
    • (2005) Leukemia , vol.19 , pp. 1774-1782
    • Burchert, A.1    Wang, Y.2    Cai, D.3
  • 28
    • 42449146501 scopus 로고    scopus 로고
    • Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
    • McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708-22.
    • (2008) Leukemia , vol.22 , pp. 708-722
    • McCubrey, J.A.1    Steelman, L.S.2    Abrams, S.L.3
  • 31
    • 46149092748 scopus 로고    scopus 로고
    • Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment
    • Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008;11:63-76.
    • (2008) Drug Resist Updat , vol.11 , pp. 63-76
    • Jiang, B.H.1    Liu, L.Z.2
  • 32
    • 37649005234 scopus 로고    scopus 로고
    • Autophagy in the pathogenesis of disease
    • Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
    • (2008) Cell , vol.132 , pp. 27-42
    • Levine, B.1    Kroemer, G.2
  • 33
    • 70349638918 scopus 로고    scopus 로고
    • Targeted therapies and autophagy: new insights from chronic myeloid leukemia
    • Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy 2009;5:1050-1.
    • (2009) Autophagy , vol.5 , pp. 1050-1051
    • Salomoni, P.1    Calabretta, B.2
  • 34
    • 70349644004 scopus 로고    scopus 로고
    • Autophagy facilitates oncogene-induced senescence
    • Narita M, Young AR, Narita M. Autophagy facilitates oncogene-induced senescence. Autophagy 2009;5:1046-7.
    • (2009) Autophagy , vol.5 , pp. 1046-1047
    • Narita, M.1    Young, A.R.2    Narita, M.3
  • 36
    • 80052697287 scopus 로고    scopus 로고
    • The role of autophagy in cancer: therapeutic implications
    • Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011;10:1533-41.
    • (2011) Mol Cancer Ther , vol.10 , pp. 1533-1541
    • Yang, Z.J.1    Chee, C.E.2    Huang, S.3    Sinicrope, F.A.4
  • 37
    • 34548188741 scopus 로고    scopus 로고
    • Self-eating and self-killing: crosstalk between autophagy and apoptosis
    • Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature 2007;8:741-52.
    • (2007) Nature , vol.8 , pp. 741-752
    • Maiuri, M.C.1    Zalckvar, E.2    Kimchi, A.3    Kroemer, G.4
  • 38
    • 48249092267 scopus 로고    scopus 로고
    • Bcl-2 family members: dual regulators of apoptosis and autophagy
    • Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008;4:600-6.
    • (2008) Autophagy , vol.4 , pp. 600-606
    • Levine, B.1    Sinha, S.2    Kroemer, G.3
  • 39
    • 84865708324 scopus 로고    scopus 로고
    • Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
    • Drullion C, Tregoat C, Lagarde V. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis 2012;3:e373.
    • (2012) Cell Death Dis , vol.3
    • Drullion, C.1    Tregoat, C.2    Lagarde, V.3
  • 40
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery 2006;5:671-88.
    • (2006) Nat Rev Drug Discovery , vol.5 , pp. 671-688
    • Faivre, S.1    Kroemer, G.2    Raymond, E.3
  • 41
    • 70349322878 scopus 로고    scopus 로고
    • Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
    • Janusa A, Linkea A, Cebula B, Robak T, Smolewski P. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drug 2009;20:693-701.
    • (2009) Anticancer Drug , vol.20 , pp. 693-701
    • Janusa, A.1    Linkea, A.2    Cebula, B.3    Robak, T.4    Smolewski, P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.